FRAX597 inhibited proliferation across five pancreatic cancer cell lines, with reported IC50 values of 0.65–2.0 μM by thymidine incorporation. These are proliferation endpoints rather than biochemical kinase potencies or direct measures of cell killing; the tested salt form was not specified. [2]
Biochemical potency and kinase selectivity
Biochemical assay · Recombinant PAK1, PAK2, PAK3 and PAK4; 106-kinase profiling panel [1]
FRAX597 inhibited group I PAKs at nanomolar concentrations in the reported enzyme assay. Profiling also identified inhibition of YES1, RET, CSF1R and TEK; it is not a PAK1-only probe.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 concentration points for enzyme IC50; 100 nM for kinase panel
- Method
- Functional kinase inhibition assays
- Reported limits
- Exact ATP concentration, concentration series and vehicle for the Z′-LYTE IC50 assay are not specified in the inspected article. The separate KinaseGlo mutant experiment uses different conditions; those are not assigned here.
Methods and source locations
Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597; hydrochloride depicted in Figure 1B
Published FRAX597 parent pharmacology with tested hydrochloride depiction; these are not measured potencies for an Adooq free-base lot. No salt conversion made.
Figure 1B–C; Results: Discovery and Characterization; Experimental Procedures: Determination of Enzyme IC50 Values
PAK1 enzymatic inhibition: 10-point Z′-LYTE fluorescence coupled-enzyme assay; duplicate concentration points — Results: Discovery and Characterization; Figure 1C (7.7 nM label, rounded to 8 nM in text)
PAK2 enzymatic inhibition: Same reported enzyme assay — Results: Discovery and Characterization; Figure 1C (12.8 nM label, rounded to 13 nM in text)
PAK3 enzymatic inhibition: Same reported enzyme assay — Results: Discovery and Characterization; Figure 1C (19.3 nM label, rounded to 19 nM in text)
PAK4 enzymatic inhibition: Same reported enzyme assay — Figure 1C and Results: Discovery and Characterization
Inhibition at 100 nM FRAX597: Reported recombinant kinase panel; kinase selectivity Methods name Z′-LYTE and Adapta formats — Results: Discovery and Characterization (panel values reported as data not shown)
FRAX597 binding in the PAK1 ATP pocket
Biochemical assay · Recombinant PAK1 kinase domain, residues 249–545, K299R mutant [1]
The reported 2 Å crystal structure places FRAX597 in the PAK1 ATP-binding pocket. The crystallographic construct contains the K299R substitution, which limits direct extrapolation of detailed interactions to native PAK1.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 mM FRAX597 for crystal soaking
- Exposure duration
- Overnight soaking
- Method
- Soaking apo-PAK1 crystals with FRAX597
- Reported limits
- Soak concentration is a crystallographic condition, not an IC50 or cellular treatment dose. Counterion in bound structure is not asserted.
Methods and source locations
Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597 ligand; study depicts starting compound as hydrochloride in Figure 1B
Binding-site evidence for the FRAX597 parent in a recombinant mutant kinase; not a measurement on the catalog lot.
Figure 2A–B; Results: Structure of PAK1 in Complex with FRAX597; Experimental Procedures: PAK1 Structure Determination
PAK1–FRAX597 complex: X-ray crystallography; PDB 4EQC — Results: Structure of PAK1 in Complex with FRAX597; Figure 2
FRAX597 localization: Complex structure and ligand difference electron density — Figure 2A–B and accompanying Results
Pancreatic cancer cell proliferation response
Cell-based study · Human PANC-1, MiaPaCa-2, BxPC-3 and murine Pan02, LM-P pancreatic cancer cells [2]
FRAX597 reduced thymidine incorporation in concentration-response experiments. The IC50 values are cellular proliferation endpoints and do not measure PAK enzyme potency or establish cell killing.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration response shown in Figure 4a; IC50 values are endpoints, not selected treatment doses
- Method
- 3H-thymidine incorporation; untreated cells normalized to 100%
- Reported limits
- Proliferation exposure duration and drug vehicle are not specified in the inspected Methods/Figure 4 caption; Methods refer to a prior protocol, not retrieved. The 24 h serum-free survival condition is not assigned to proliferation.
Methods and source locations
Compound reported in the paper: FRAX597; Compound label in the paper: FRAX597 purchased from SYNthesis (Parkville, Australia); salt form not stated
Named FRAX597 literature evidence; applicability is at parent-compound level, with tested salt unspecified.
Figure 4a and caption; Table 2; Methods: Cells and reagents; Cell proliferation, cell survival and combination index; Statistical analysis
PANC-1 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis
MiaPaCa-2 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis
BxPC-3 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis
Pan02 proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis
LM-P proliferation: 3H-thymidine incorporation; three independent experiments, experiments done in duplicate according to statistics section — Table 2, FRAX IC50 proliferation column; Figure 4a and caption; Statistical analysis